Spark Therapeutics, Inc. (NASDAQ:ONCE) insider Daniel Faga sold 6,000 shares of the business’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $82.50, for a total transaction of $495,000.00. Following the completion of the transaction, the insider now owns 6,000 shares in the company, valued at $495,000. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Daniel Faga also recently made the following trade(s):

  • On Thursday, September 7th, Daniel Faga sold 3,000 shares of Spark Therapeutics stock. The shares were sold at an average price of $85.02, for a total transaction of $255,060.00.
  • On Monday, July 24th, Daniel Faga sold 3,000 shares of Spark Therapeutics stock. The shares were sold at an average price of $70.00, for a total transaction of $210,000.00.
  • On Thursday, June 29th, Daniel Faga sold 4,500 shares of Spark Therapeutics stock. The shares were sold at an average price of $62.71, for a total transaction of $282,195.00.

Spark Therapeutics, Inc. (ONCE) opened at 81.88 on Friday. The stock has a 50 day moving average of $82.07 and a 200 day moving average of $73.77. The firm’s market capitalization is $2.56 billion. Spark Therapeutics, Inc. has a one year low of $35.07 and a one year high of $85.26.

Spark Therapeutics (NASDAQ:ONCE) last released its earnings results on Wednesday, August 2nd. The biotechnology company reported ($1.89) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.75) by ($0.14). Spark Therapeutics had a negative net margin of 962.72% and a negative return on equity of 59.74%. The company had revenue of $1.48 million during the quarter, compared to analysts’ expectations of $1.33 million. During the same quarter in the previous year, the firm posted ($1.04) earnings per share. Spark Therapeutics’s revenue for the quarter was up 14.7% compared to the same quarter last year. Analysts forecast that Spark Therapeutics, Inc. will post ($7.69) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/16/daniel-faga-sells-6000-shares-of-spark-therapeutics-inc-once-stock.html.

Institutional investors have recently added to or reduced their stakes in the stock. Ameritas Investment Partners Inc. grew its holdings in Spark Therapeutics by 23.6% in the second quarter. Ameritas Investment Partners Inc. now owns 2,040 shares of the biotechnology company’s stock valued at $122,000 after purchasing an additional 389 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in Spark Therapeutics in the second quarter valued at approximately $143,000. BNP Paribas Arbitrage SA grew its holdings in Spark Therapeutics by 530.1% in the second quarter. BNP Paribas Arbitrage SA now owns 2,911 shares of the biotechnology company’s stock valued at $174,000 after purchasing an additional 2,449 shares during the period. Pacad Investment Ltd. grew its holdings in Spark Therapeutics by 75.0% in the second quarter. Pacad Investment Ltd. now owns 3,500 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 1,500 shares during the period. Finally, Highbridge Capital Management LLC purchased a new stake in Spark Therapeutics in the first quarter valued at approximately $227,000. Hedge funds and other institutional investors own 91.01% of the company’s stock.

Several research firms have weighed in on ONCE. Jefferies Group LLC reiterated a “buy” rating and issued a $95.00 target price (up from $85.00) on shares of Spark Therapeutics in a report on Thursday, August 3rd. Evercore ISI began coverage on shares of Spark Therapeutics in a report on Wednesday, August 16th. They issued an “in-line” rating and a $83.00 target price on the stock. Zacks Investment Research upgraded shares of Spark Therapeutics from a “strong sell” rating to a “hold” rating in a report on Wednesday, July 19th. Chardan Capital reiterated a “neutral” rating on shares of Spark Therapeutics in a report on Monday, July 24th. Finally, BidaskClub upgraded shares of Spark Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Two research analysts have rated the stock with a sell rating, two have given a hold rating and fifteen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average target price of $84.78.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Insider Buying and Selling by Quarter for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.